Cendakimab Emerging Drug Insight and Market Forecast - 2032

This “Cendakimab Emerging Drug Insight and Market Forecast - 2032” report provides comprehensive insights about cendakimab for eosinophilic esophagitis (EoE) in the seven major markets. A detailed picture of the cendakimab for EoE in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the cendakimab for EoE. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the cendakimab market forecast analysis for EoE in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in EoE.

Drug Summary

Cendakimab/RPC4046/CC-93538 is a recombinant humanized, high affinity, selective, anti-IL-13 mAb. RPC4046 binds an IL-13 epitope that prevents its binding to both IL-13R (alpha) 1 and IL-13R (alpha) 2, providing potential efficacy and/or safety advantages. The drug has been granted ODD for the treatment of EoE by the US FDA. In the Phase II study, RPC4046 demonstrated positive results, and currently, the company is conducting two Phase III clinical studies to evaluate the efficacy and safety of CC-93538 in adult and adolescent participants with EoE.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the cendakimab description, mechanism of action, dosage and administration, research and development activities in eosinophilic esophagitis (EoE).
• Elaborated details on cendakimab regulatory milestones and other development activities have been provided in this report.
• The report also highlights the cendakimab research and development activities in EoE across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around cendakimab.
• The report contains forecasted sales of cendakimab for EoE till 2032.
• Comprehensive coverage of the late-stage emerging therapies for EoE.
• The report also features the SWOT analysis with analyst views for cendakimab in EoE.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Cendakimab Analytical Perspective

In-depth Cendakimab Market Assessment

This report provides a detailed market assessment of cendakimab for eosinophilic esophagitis (EoE) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2026 to 2032.

Cendakimab Clinical Assessment

The report provides the clinical trials information of cendakimab for EoE covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for eosinophilic esophagitis (EoE) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence cendakimab dominance.
• Other emerging products for EoE are expected to give tough market competition to cendakimab and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of cendakimab in EoE.
• This in-depth analysis of the forecasted sales data of cendakimab from 2026 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the cendakimab in EoE.

Key Questions

• What is the product type, route of administration and mechanism of action of cendakimab?
• What is the clinical trial status of the study related to cendakimab in eosinophilic esophagitis (EoE) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the cendakimab development?
• What are the key designations that have been granted to cendakimab for EoE?
• What is the forecasted market scenario of cendakimab for EoE?
• What are the forecasted sales of cendakimab in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to cendakimab for EoE?
• Which are the late-stage emerging therapies under development for the treatment of EoE?

This product will be delivered within 2 business days.